1. Home >
  2. Investors >
  3. Private Equity Firm >
  4. Belgium >
  5. GIMV >
  6. M&A

GIMV Mergers & Acquisitions

GIMV M&A Summary

In the last 3 years, GIMV has acquired 10 companies. It has also invested in 13 others.

In the last 3 years, GIMV has exited 17 companies. The Firm’s most common exit type is trade sale (53%). GIMV’s largest (disclosed) exit occurred in 2013 when it sold Astex Pharmaceuticals for $886M.

Sign-up to view GIMV’s full profile and discover more large private equity firm investors just like it.

M&A Summary

  • M&A Total Activity280
    • M&A Buy Activity169
    • M&A Sell Activity111
  • M&A Buy/Sell Connections86

GIMV

Gimv NV

Karel Oomsstraat 37,
Antwerp, B-2018
Belgium
+32 3 290.21.00
www.gimv.com
info@gimv.com

All (280) Buy (169) Sell (111)
Date Target Value
$mlns 		Transaction Type Acquirer Seller SRC
Link
2025-10-22 Imcheck Therapeutics · Life Science
Marseilles, France · www.imchecktherapeutics.com

ImCheck Therapeutics is a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel superfamily of immunomodulators. Its clinical-stage program, ICT01, has been advancing to late-stage trials, demonstrating a unique mechanism of action that modulates both innate and adaptive immunity. These “first-in-class” activating antibodies may deliver superior clinical outcomes compared to first-generation immunotherapy approaches, in particular in rational combinations with immune checkpoint inhibitors and immunomodulatory anti-cancer drugs. Imcheck Therapeutics was founded in 2015 and is based in Marseilles, France.

Advisors: Centerview Partners , Dentons , Goodwin Procter 		- Add-on Acquisition

Ipsen
Advisor: A&O Shearman

Andera Partners PE

Bpifrance Investissement PE

EQT Life Sciences PE

GIMV PE


Try Mergr Free — See This and 220,573+
Other Company and Investor Profiles Today

Try free. Full access. Cancel anytime.

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
Try Free

What's Mergr?

Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.

We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.

With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.8K Private Equity Firms
  • 214K M&A Transactions
  • 216K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.8K M&A Advisors
    (Investment Banks and Law Firms)
  • 83K M&A Contacts
    (PE and M&A Advisors)

What next?

Try Free

Full access to Mergr's investor, acquirer, and transaction data starts here.

Mergr

Solution for

Product

Company

Legal